ARAY Quote, Financials, Valuation and Earnings

Apyx Medical Corp. has a net margin of -13.47% compared to Accuray, Inc.'s net margin of -15.18%. Accuray, Inc.'s return on equity of -60.6% beat Apyx Medical Corp.'s return on equity of -146.08%.

Accuray, Inc. has a consensus price target of $2.53, signalling upside risk potential of 331.7%. On the other hand Apyx Medical Corp. has an analysts' consensus of $6.00 which suggests that it could grow by 71.43%. Given that Accuray, Inc. has higher upside potential than Apyx Medical Corp., analysts believe Accuray, Inc. is more attractive than Apyx Medical Corp..

Accuray, Inc. has a beta of 1.151, which suggesting that the stock is 15.124% more volatile than S&P 500. In comparison Apyx Medical Corp. has a beta of 1.592, suggesting its more volatile than the S&P 500 by 59.181%.

Accuray, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Apyx Medical Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Accuray, Inc. pays -- of its earnings as a dividend. Apyx Medical Corp. pays out -- of its earnings as a dividend.

Accuray, Inc. quarterly revenues are $102.2M, which are larger than Apyx Medical Corp. quarterly revenues of $12.9M. Accuray, Inc.'s net income of -$13.8M is lower than Apyx Medical Corp.'s net income of -$2M. Notably, Accuray, Inc.'s price-to-earnings ratio is 149.00x while Apyx Medical Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Accuray, Inc. is 0.15x versus 2.93x for Apyx Medical Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Alphatec Holdings, Inc. has a net margin of -13.47% compared to Accuray, Inc.'s net margin of -10.21%. Accuray, Inc.'s return on equity of -60.6% beat Alphatec Holdings, Inc.'s return on equity of -1092.5%.

Accuray, Inc. has a consensus price target of $2.53, signalling upside risk potential of 331.7%. On the other hand Alphatec Holdings, Inc. has an analysts' consensus of $24.62 which suggests that it could grow by 75.7%. Given that Accuray, Inc. has higher upside potential than Alphatec Holdings, Inc., analysts believe Accuray, Inc. is more attractive than Alphatec Holdings, Inc..

Accuray, Inc. has a beta of 1.151, which suggesting that the stock is 15.124% more volatile than S&P 500. In comparison Alphatec Holdings, Inc. has a beta of 1.013, suggesting its more volatile than the S&P 500 by 1.34%.

Accuray, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alphatec Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Accuray, Inc. pays -- of its earnings as a dividend. Alphatec Holdings, Inc. pays out -- of its earnings as a dividend.

Accuray, Inc. quarterly revenues are $102.2M, which are smaller than Alphatec Holdings, Inc. quarterly revenues of $212.9M. Accuray, Inc.'s net income of -$13.8M is higher than Alphatec Holdings, Inc.'s net income of -$21.7M. Notably, Accuray, Inc.'s price-to-earnings ratio is 149.00x while Alphatec Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Accuray, Inc. is 0.15x versus 2.75x for Alphatec Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Boston Scientific Corp. has a net margin of -13.47% compared to Accuray, Inc.'s net margin of 12.68%. Accuray, Inc.'s return on equity of -60.6% beat Boston Scientific Corp.'s return on equity of 12.55%.

Accuray, Inc. has a consensus price target of $2.53, signalling upside risk potential of 331.7%. On the other hand Boston Scientific Corp. has an analysts' consensus of $104.75 which suggests that it could grow by 38.28%. Given that Accuray, Inc. has higher upside potential than Boston Scientific Corp., analysts believe Accuray, Inc. is more attractive than Boston Scientific Corp..

Accuray, Inc. has a beta of 1.151, which suggesting that the stock is 15.124% more volatile than S&P 500. In comparison Boston Scientific Corp. has a beta of 0.666, suggesting its less volatile than the S&P 500 by 33.441%.

Accuray, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Boston Scientific Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Accuray, Inc. pays -- of its earnings as a dividend. Boston Scientific Corp. pays out -- of its earnings as a dividend.

Accuray, Inc. quarterly revenues are $102.2M, which are smaller than Boston Scientific Corp. quarterly revenues of $5.3B. Accuray, Inc.'s net income of -$13.8M is lower than Boston Scientific Corp.'s net income of $670M. Notably, Accuray, Inc.'s price-to-earnings ratio is 149.00x while Boston Scientific Corp.'s PE ratio is 39.06x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Accuray, Inc. is 0.15x versus 5.64x for Boston Scientific Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Plus Therapeutics, Inc. has a net margin of -13.47% compared to Accuray, Inc.'s net margin of -316.61%. Accuray, Inc.'s return on equity of -60.6% beat Plus Therapeutics, Inc.'s return on equity of --.

Accuray, Inc. has a consensus price target of $2.53, signalling upside risk potential of 331.7%. On the other hand Plus Therapeutics, Inc. has an analysts' consensus of $5.50 which suggests that it could grow by 1595.96%. Given that Plus Therapeutics, Inc. has higher upside potential than Accuray, Inc., analysts believe Plus Therapeutics, Inc. is more attractive than Accuray, Inc..

Accuray, Inc. has a beta of 1.151, which suggesting that the stock is 15.124% more volatile than S&P 500. In comparison Plus Therapeutics, Inc. has a beta of 0.886, suggesting its less volatile than the S&P 500 by 11.364%.

Accuray, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Plus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Accuray, Inc. pays -- of its earnings as a dividend. Plus Therapeutics, Inc. pays out -- of its earnings as a dividend.

Accuray, Inc. quarterly revenues are $102.2M, which are larger than Plus Therapeutics, Inc. quarterly revenues of $1.4M. Accuray, Inc.'s net income of -$13.8M is lower than Plus Therapeutics, Inc.'s net income of -$4.4M. Notably, Accuray, Inc.'s price-to-earnings ratio is 149.00x while Plus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Accuray, Inc. is 0.15x versus 5.20x for Plus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.